It’s ironic that the rigid nature of clinical research depends on a largely fragile variable: people.
Even the most promising therapy cannot succeed in development if the study evaluating it struggles to keep participants engaged. Recruiting patients is already a significant challenge for sponsors. But the true test of trial success often comes after enrollment, when an estimated 40% of patients are likely to become non-adherent and approximately 30% will drop out altogether.
As it is, trial sponsors spend north of $6,500 to recruit a single participant, and replacing a patient lost to non-adherence can cost over $19,500. Beyond the financial burden, participant dropout delays trials and compromises the scientific integrity of the data being collected. Non-adherence can erode statistical power, introduce variability into the dataset, and complicate dose-response evaluation. Inconsistent dosing or missed assessments create noise that obscures the true treatment effect, potentially leading to incomplete or misleading conclusions about a therapy’s efficacy. Ultimately, patient dropout can weaken regulatory confidence in trial outcomes and delay the delivery of new treatments to patients.
The stakes are too high to keep the status quo. Patient retention can no longer be viewed as a downstream operational challenge. It must be a strategic design priority. Fortunately, advances in behavioral science and machine learning are enabling sponsors to move beyond reactive compliance monitoring and toward a proactive model of participant engagement.
The Hidden Drivers of Patient Disengagement
One of the most persistent misconceptions in clinical operations is that patient dropout is triggered by an external event — an inconvenient visit schedule, a complicated dosing regimen, or a missed appointment. But the true drivers of disengagement tend to be deeply human and highly individualized.
Participants may feel overwhelmed by the perceived burden of study requirements. Motivation may decline as competing life priorities emerge. Emotional stress, health literacy challenges, transportation barriers, or caregiving responsibilities can all influence a participant’s ability to remain engaged. Two patients can experience the exact same protocol yet respond very differently based on their personality traits, beliefs and personal circumstances. That variability makes adherence difficult to manage using a traditional, one-size-fits-all approach.
The good news is, emerging analytical capabilities are allowing sponsors to better understand these dynamics. Advances in behavioral science and machine learning now make it possible to quantify engagement factors that were previously considered intangible. Motivation, perceived burden, and psychological readiness to name a few. These insights allow study teams to detect early signs of disengagement long before they manifest as protocol deviations or dropout.
From Reactive Compliance to Predictive Engagement
Machine learning excels at identifying subtle patterns across complex datasets. For clinical trials, these models can analyze behavioral, contextual, and operational signals to detect emerging adherence risks earlier than traditional monitoring approaches. For example, predictive models may identify low participant confidence, high perceived burden, or life circumstances likely to interfere with study participation. These signals may be small individually, but together they can reveal a trajectory toward disengagement.
Importantly, machine learning is not meant to replace clinical judgment or site expertise. Instead, it provides study teams with a predictive behavioral lens, one that enables earlier, more informed intervention.
Rather than reacting to missed visits or compliance violations, sponsors can begin to anticipate participant needs and address potential barriers before they escalate. This shift from reaction to anticipation represents one of the most meaningful changes underway in clinical trial operations. Retention is no longer simply something to fix when problems arise. Instead, it becomes an outcome that can be intentionally designed for.
Why Behavioral Science Matters
If disengagement is fundamentally behavioral, then effective solutions must be grounded in behavioral science.
Understanding what motivates participants, how they perceive study burden, and what external pressures may influence their participation provides critical information for designing engagement strategies. Behavioral science offers frameworks that help explain why participants struggle and what kinds of support are most likely to help them stay on track.
When behavioral insights are combined with machine learning, they can be translated into measurable engagement variables rather than abstract psychological concepts. This creates a powerful foundation for predictive modeling.
Sponsors can begin to identify not only who may be at risk of disengaging, but also why. Armed with that understanding, technology platforms can deliver adaptive, personalized support tailored to each participant’s circumstances.
Moving Beyond Reminder-Based Engagement
Many existing adherence tools rely on simple reminders: notifications to complete a diary entry, attend a visit, or take a medication dose. While helpful, reminders alone rarely address the root causes of disengagement.
Personalized digital engagement takes a fundamentally different approach. Traditional reminder systems focus on tasks. Personalized engagement focuses on people.
Instead of simply prompting participants to complete an action, modern engagement platforms can tailor communications based on individual risk profiles. Participants who show signs of lower health literacy might receive simplified educational materials. Those experiencing higher perceived burden could receive supportive messages acknowledging the challenges of participation and offering practical guidance. Communication tone, timing, and content can all be adapted to match the participant’s behavioral context.
In practice, this might include sending messages that acknowledge emotional challenges, adjusting the cadence of communications for individuals experiencing study fatigue, or providing targeted support resources when signs of stress emerge.
These interventions may appear small on the surface, but they address the deeper factors that influence sustained engagement.
Implementing AI Without Overengineering Trials
For sponsors eager to adopt AI-driven engagement strategies, the biggest challenge is often knowing where to start. The key is strategic clarity rather than technological ambition.
Sponsors should begin with three guiding principles: simplicity, interoperability, and purpose.
Simplicity ensures that new tools reduce friction rather than introducing additional complexity for sites or participants. Interoperability allows engagement platforms to integrate seamlessly with existing systems such as electronic data capture, electronic clinical outcome assessments, and clinical trial management systems. Purpose requires sponsors to clearly define the specific challenge they are trying to address, whether it is early adherence risk detection, improved participant support, or reduced study burden.
Ultimately, the organizations that will lead the next decade of clinical research will not necessarily be those deploying the most technology. They will be the ones deploying technology with intention.
The Future of Patient-Centered Trials
As clinical trials become more complex, decentralized, and patient-dependent, predictive engagement models will likely become a standard component of trial design. Achieving this shift will require continued collaboration across clinical operations, behavioral science, and data science teams. It will also require technologies that integrate seamlessly into existing workflows while minimizing burden for both sites and participants.
A focus on people vs. compliance means trial participants are not simply viewed as data contributors, but as individuals navigating real-world challenges while participating in research.
When sponsors begin to anticipate challenges and design trials around human behavior rather than operational assumptions, retention stops being a persistent problem and instead becomes a predictable and manageable outcome.
Author Bio:
Dominique Demolle is the CEO and cofounder of Cognivia, an AI-based tech company that works with top-tier pharmaceutical and biotech companies to reduce dropout risk and nonadherence in clinical trials.
Disclaimer: This guest commentary reflects the author’s analysis and is provided for informational purposes only; it does not constitute medical, legal, or official editorial advice from Life Science Daily News. The author is CEO and Co-Founder of Cognivia, an AI-based technology company working with pharmaceutical and biotech companies to reduce dropout risk and nonadherence in clinical trials.
